Psychedelic Spotlight News

  • Interview with Zoe Helene, Founder of Cosmic Sister

    Listen, Podcasts

    In our conversation, we discuss some of Zoe’s formative experiences in the creative arts which led her down the path of plant medicine advocacy, core feminist issues and how psychedelics play a role in furthering women’s movements, why an emphasis on equity and representation within the budding psychedelic industry is crucial and still has a long way to go, and so much more.

  • A NEW Psilocybin-Depression Study Was Just Released: The Results Are BREATHTAKING | GAME OVER?🚀🍄

    Listen, Videos

    A NEW Psilocybin-Depression Study Was Just Released: The Results Are BREATHTAKING | GAME OVER?🚀🍄

    Hello Psychedelic Investors! It’s an early Christmas today, as the results of a psilocybin to treat depression study were released. And the results are fantastic.
    This study, which used Comp 360, Compass Pathways’ (NASDAQ: CMPS) proprietary formulation of psilocybin (the active ingredient magic mushrooms) to treat Major Depressive Disorder, had fantastic results. 50% of people improved so much that they entered remission, and another 30% improved by more than 50%.
    For any followers of Psychedelic Stocks, this is amazing news, and it bodes well for Compass Pathways’ phase 2b psilocybin to treat treatment-resistant depression trials. As a reminder, this trial will be the most important event for psychedelic investors, as it is the largest ever psychedelic clinical trial. It is also the furthest advanced psilocybin clinical trial, being in phase 2b.
    Even if you don’t like Compass Pathways, this is very exciting news. This will benefit the entire psychedelics industry, including companies like MindMed (MNMD), Red Light Holland (TRIP), atai Life Sciences (atai) and more.
    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media!
    Instagram: @psychedelicinvestor
    James Twitter: @PSY_Invest
    Maria’s Twitter: @PSY_Holy

    Facebook: @thepsychedelicinvestor

    Email: thepsychedelicinvestor@gmail.com

    Music: www.bensound.com

    Reference: https://psilocybinalpha.com/news/open-label-study-of-comp360-psilocybin-therapy-for-depression-in-cancer-patients-demonstrates-feasibility-of-simultaneous-psilocybin-administration-in-small-groups

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #CompassPathways #Psilocybin #Psychedelics